Press Release
Full Year 2025 Results:Atos Group has Delivered on its Commitments to Restore its Foundations
Growth Chapter Ready to be OpenedFY 2025 financial and extra financial targets met or exceeded:Revenue at €8,001 million, reflecting a clear improvement in the organic growth trajectory in Q4
Operating margin at €351 million, representing 4.4% of revenue, doubling year-on-year
Net change in cash1 limited to €-326 million despite faster than expected execution of the restructuring program
Greenhouse gas emissions reduced by 58% compared with the 2019 baseline.Execution of Genesis strategic and transformation plan ahead of schedule, with 88%2 of the three-year savings target completed in less than one year
Strengthened commercial traction, with early signs of renewed client confidence
Scaling artificial intelligence (AI) from...
Fagron publishes its Annual Report 2025
Written by Customer Service on . Posted in Public Companies.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET
Fagron publishes its Annual Report 2025
Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron’s annual financial results for the financial year 2025 on February 12, 2026.
The Annual Report is available on Fagron’s website in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated financial statements, as well as the sustainability report, for the financial year 2025.
The Annual Report will be presented to the Annual General Meeting of Shareholders, scheduled to be held on May 11, 2026.
Financial calendar 9 April 2026 Trading...
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Written by Customer Service on . Posted in Public Companies.
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG
Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART’s efficacy and safety across subtypes
New biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART’s expanding treatment approach in CIDPMarch 6, 2026, 7:00 AM CEST
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidates empasiprubart and adimanebart at the 2026 American Academy...
Hexagon Purus receive orders for delivery of hydrogen distribution units to a leading European energy company
Written by Customer Service on . Posted in Public Companies.
(Oslo, 6 March 2026) Hexagon Purus, a world leading manufacturer of zero emission mobility and infrastructure solutions, has received purchase orders for the delivery of hydrogen distribution units from a leading Central European integrated energy company.
The total value of the order is approximately EUR 6.2 million and is scheduled for delivery in Q3 and Q4 2026.
“We are happy to welcome this new customer and to provide distribution units that will transport hydrogen to this leading European energy company’s growing mobility infrastructure network”, says Morten Holum, CEO of Hexagon Purus. “This order is a direct result of our recent efforts to diversify the customer base and contributes to strengthening our order book for the second half of 2026”.
For more information:
Mathias Meidell, Investor Relations Director, Hexagon PurusTelephone:...
SPIE – 2025 Full-Year results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
High-quality performance with outstanding cash generation
Upgraded mid-term margin target
Governance evolution, ensuring smooth transition and full strategic continuityCergy, March 6th, 2026
Record profitability and solid revenue growth, pushing revenue well above the €10 bn markRevenue: €10,380 million, up +4.8% vs. 2024, including +3.2% growth from acquisitions and +2.0% organic growth, with Germany confirmed as the Group’s primary growth driver (+5.3%), well supported by North-Western Europe (+4.3%)
EBITA increased sharply by 11.4% to €793 million, with the margin reaching a record 7.6% (+40 bps), driven by pricing power, selectivity, operational excellence and accretive acquisitions
Adjusted net income1: €458 million (+9% vs. 2024)
Recommended dividend: €1.08 per share2, up 8% Another year of outstanding free cash flow€524...
REalloys Announces Pricing of Upsized $50 Million Public Offering
Written by Customer Service on . Posted in Public Companies.
BOCA RATON, Fla., March 06, 2026 (GLOBE NEWSWIRE) — REalloys Inc. (NASDAQ: ALOY) (the “Company” or “REalloys”), a U.S.-based mine-to-magnet rare earth company, today announced the pricing of its previously announced underwritten public offering of 2,702,702 shares of its common stock at a public offering price of $18.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 396,963 shares of common stock. The offering is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions.
Clear Street is acting as lead book-running manager for the offering.
Needham & Company is acting as joint book-running manager for the offering.
Laidlaw & Company (UK) Ltd. and Muriel Siebert & Co. are acting as co-managers for the offering.
Cantor...
DMG Blockchain Solutions Announces 75 MW Utility Approval Expanding Christina Lake Data Center Power, February Preliminary Operational Results
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG”), a leading vertically integrated blockchain and data center technology company, announces it has received verbal approval by its utility for an additional 10 megawatts of non-firm power. This raises DMG’s total available power capacity to 75 megawatts based on a combination of 15 megawatts of firm power and 60 megawatts of non-firm (curtailable) power. While the Company has previously submitted an application for 150 megawatts of firm power, it now plans to submit a new application for additional non-firm power, which, if approved, may be more readily available at a lower capital cost.
DMG’s use of non-firm power has been an unqualified success to date. It has not only helped to modestly...
Quipt Home Medical Receives Final Order Approving Arrangement
Written by Customer Service on . Posted in Mergers And Acquisitions.
CINCINNATI, March 05, 2026 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announces that the Supreme Court of British Columbia issued a final order today in connection with the previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”) pursuant to which affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC will acquire all of the issued and outstanding common shares of the Company (each, a “Share”) for cash consideration of US$3.65 per Share. The final order was the final substantive court approval required prior to the closing of the Arrangement. Assuming all other terms and conditions to the Arrangement are satisfied,...
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce closing of its previously announced non-brokered private placement of convertible debenture units (“Debenture Units”) for aggregate gross proceeds of $1,000,000 (the “Debenture Private Placement”). The Company also announces that it has entered into the previously announced debt settlement agreements with holders of the 12.0% unsecured convertible debentures of the Company (the “Existing Debentures”) to settle an aggregate outstanding debt of $1,587,130.59 (the “Settled Amount”), comprised of a principal amount of $1,454,000.00 and accrued interest of $133,130.59...
Mission Success: Rocket Lab Completes 83rd Launch
Written by Customer Service on . Posted in Public Companies.
MAHIA, New Zealand, March 05, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, has today turned around its second successful launch in less than a week from two different countries, maintaining Rocket Lab’s position as the global leader in small launch.
The “Insight At Speed Is A Friend Indeed” mission lifted off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on March 6th at 12:53 p.m. NZDT to deploy a single commercial satellite to a 470 km low Earth orbit for a confidential customer. The satellite was also deployed from a Rocket Lab Motorized Lightband, a separation system for satellites with 100% mission success that showcases the streamlined service Rocket Lab delivers customers from across its vertically-integrated launch...
